| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Chlorisondamine diiodide targets nicotinic acetylcholine receptors (nAChRs), acting as a potent antagonist. It has an IC50 of 1.8 µM in rat striatal synaptosomes. It also acts as a ganglion blocker, specifically targeting ganglionic transmission. By blocking nAChRs, the compound decreases dopamine release induced by nicotine and antagonizes some of nicotine's central actions.
|
|---|---|
| ln Vitro |
In vitro, Chlorisondamine diiodide is a potent nAChR antagonist with an IC50 of 1.8 µM in rat striatal synaptosomes. The compound blocks the effects of acetylcholine on the sympathetic nervous system. It decreases dopamine release induced by nicotine. Detailed in vitro studies have characterized its receptor binding and functional antagonism at nAChRs.
|
| ln Vivo |
At one and two weeks, the dose-dependent inhibitory effect of nicotine on vertical activity (0–20 min) is countered by chlorsultanamine (0.2, 1.0, 5.0 μg; intravenous; single dose) [1].
In vivo, Chlorisondamine diiodide is used as a pharmacological tool to block the effects of acetylcholine on the sympathetic nervous system. It antagonizes some of nicotine's central actions in a potent, long-lasting and pharmacologically selective way. The compound has been extensively studied for its therapeutic and toxic effects. |
| Enzyme Assay |
Chlorisondamine diiodide's receptor binding activity has been characterized using rat striatal synaptosomes. Binding assays typically involve measuring the displacement of radiolabeled nAChR ligands using filtration or centrifugation methods. The compound has an IC50 of 1.8 µM for nAChR antagonism. Functional assays measure the inhibition of nAChR-mediated ion flux or neurotransmitter release.
|
| Cell Assay |
In vitro cell experiments with Chlorisondamine diiodide typically use neuronal cell lines or synaptosomal preparations expressing nAChRs. Cells or synaptosomes are treated with the compound at various concentrations, and nAChR activity is measured using radioligand binding, ion flux assays, or neurotransmitter release assays. The compound's effects on dopamine release and nicotine-induced responses are assessed.
|
| Animal Protocol |
Animal/Disease Models: Rat (subcutaneous injection of nicotine 0.4 mg/kg once) [1]
Doses: 0.2, 1.0, 5.0 μg Route of Administration: intravenous (iv) (iv)injection; single dose Experimental Results: antagonism in a dose-dependent manner at 1 and 2 weeks Inhibitory effects of nicotine on vertical activity (0-20 min). In vivo animal studies with Chlorisondamine diiodide have been conducted using rodent models to study nicotinic receptor function and ganglionic transmission. The compound is typically administered via injection. Detailed protocols regarding dosage, treatment duration, and specific animal models are not extensively reported. |
| ADME/Pharmacokinetics |
Pharmacokinetic data specific to Chlorisondamine diiodide are limited in the available literature. As a quaternary ammonium compound, it is expected to have limited oral bioavailability and poor blood-brain barrier penetration. The compound is primarily used as a research tool for studying nAChR function and ganglionic transmission.
|
| Toxicity/Toxicokinetics |
Chlorisondamine diiodide is considered safe for research use at typical concentrations. As a research compound, it is intended for laboratory use only and not for human consumption. The compound should be handled under standard laboratory safety practices with appropriate precautions.
|
| References |
|
| Additional Infomation |
Chlorisondamine diiodide has a molecular formula of C14H20Cl4N2•2I and a molecular weight of 611.95. The compound appears as a white to beige powder. It is a potent nAChR antagonist (IC50 = 1.8 µM) and a ganglion blocker. It is commonly used in research to block the effects of acetylcholine on the sympathetic nervous system.
|
| Molecular Formula |
C14H20N2CL4+2.2[I-]
|
|---|---|
| Molecular Weight |
611.942
|
| Exact Mass |
609.847
|
| CAS # |
96750-66-2
|
| PubChem CID |
16078959
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
336
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
FPNVAOZHQUJJJQ-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C14H20Cl4N2.2HI/c1-19(2,3)5-6-20(4)7-9-10(8-20)12(16)14(18)13(17)11(9)15;;/h5-8H2,1-4H3;2*1H/q+2;;/p-2
|
| Chemical Name |
trimethyl-[2-(4,5,6,7-tetrachloro-2-methyl-1,3-dihydroisoindol-2-ium-2-yl)ethyl]azanium;diiodide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6341 mL | 8.1707 mL | 16.3415 mL | |
| 5 mM | 0.3268 mL | 1.6341 mL | 3.2683 mL | |
| 10 mM | 0.1634 mL | 0.8171 mL | 1.6341 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
